Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • EDI Action Plan
    • Leadership
    • Team
    • Annual Report
    • Publications
    • Careers
  • Brain Conditions
    • One Brain
    • ALS
    • Autism (ASD)
    • Brain Cancer
    • Brain Injury
    • Dementia
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • More
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
    • Research Impact Stories
    • Equity, Diversity and Inclusion
    • Brain Health in Indigenous Communities
    • Women’s Brain Health
    • Mind Over Matter
  • How You Can Help
    • Ways to Give
    • Start a Fundraiser
    • Workplace Giving
    • The Great Minds

Funded Grants

Back to results

Amyloid beta oligomers: refining the therapeutic target through photolabelling and fractionation

Project Overview

We know that Alzheimer’s disease is caused by the clumping together of misfolded proteins in the brain, specifically two proteins called amyloid beta and tau. We know that new antibody treatments for Alzheimer’s disease target the surface of clumps of amyloid beta and remove the clumps from the brain. Unfortunately, these drugs have significant side effects such as brain swelling and bleeding and don’t stop the disease. How can we improve on these treatments?
We believe the drugs don’t work well because they are targeting the surface of the wrong shape of clumped protein. Many different proteins can form clumps of different sizes and shapes in the brain during dementia, but only some of these are responsible for the disease. We plan to identify all the potential disease-causing protein clumps as they exist in the brain, then use this information to suggest new targets for drug therapy.
Previous studies of protein clumps rely on first purifying them from brain. Unfortunately, this step can change their shape and surface. We will avoid this by applying a paint-like coating to the clumps before purification. This will mark all the surface parts of the proteins. Then we can purify and analyze all the clumps to determine what the starting clumps looked like, based on which surfaces are painted, like reassembling a jigsaw puzzle.
The goal is to identify the most relevant protein targets for therapy. We have drugs that can remove protein clumps from the brain successfully, but currently they have significant side effects and don’t stop the disease. By capturing the full range of clumps that are actually in the brain before purification, we may find more relevant protein targets for the creation of more effective therapy with fewer side effects.
For so long we have had no therapies to offer that can actually stop the disease. We are now in a new era of drugs that can get rid of the clumps of protein that we think cause the disease. This is generating tremendous hope that a cure is around the corner. We just need to define exactly which clumps of protein are the most relevant to target. This project aims to do just that.

Principal Investigator

Valerie Sim , University of Alberta

Partners and Donors

Alzheimer Society of Canada

Project Ongoing

Amyloid beta oligomers: refining the therapeutic target through photolabelling and fractionation

  • Grant Type

    Capacity building grants

  • Area of research

    Neurodegeneration

  • Disease Area

    Alzheimer’s

  • Competition

    Alzheimer Society Research Program (ASRP)

  • Province

    Alberta

  • Start Date

    2024

  • Total Grant Amount

    $100,000

  • Health Canada Contribution

    $50,000

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

+1 (514) 989-2989 info@braincanada.ca

Please note all online donations will receive an electronic tax receipt, issued by Brain Canada Foundation.

Our Donors

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign Up

Territorial acknowledgement

The offices of Brain Canada Foundation are located on the traditional, ancestral territory of the Kanien'kehá:ka Peoples, a place which has long served as a site of meeting and exchange amongst nations. We honour and pay respect to elders past, present and emerging, and dedicate ourselves to moving forward in the spirit of partnership, collaboration, and reconciliation. In our work, we focus our efforts on the Truth and Reconciliation Commission’s Calls to Action, particularly those that pertain to improving health for Indigenous Peoples and that focus on advancing our own learning on Indigenous issues.

© 2025 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co

  • About
    • What We Do
    • EDI Action Plan
    • Leadership
    • Team
    • Annual Report
    • Publications
    • Careers
  • Brain Conditions
    • One Brain
    • ALS
    • Autism (ASD)
    • Brain Cancer
    • Brain Injury
    • Dementia
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • More
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
    • Research Impact Stories
    • Equity, Diversity and Inclusion
    • Brain Health in Indigenous Communities
    • Women’s Brain Health
    • Mind Over Matter
  • How You Can Help
    • Ways to Give
    • Start a Fundraiser
    • Workplace Giving
    • The Great Minds
Project Directory
Donate Now